Updated guidelines for chronic active Epstein-Barr virus disease
- PMID: 37728704
- PMCID: PMC10615970
- DOI: 10.1007/s12185-023-03660-5
Updated guidelines for chronic active Epstein-Barr virus disease
Abstract
Chronic active Epstein-Barr virus disease (CAEBV), formerly named chronic active Epstein-Barr virus infection, is characterized by systemic inflammation and clonal proliferation of Epstein-Barr virus (EBV)-infected T or NK cells. As CAEBV is a potentially life-threatening illness, appropriate diagnosis and therapeutic interventions are necessary for favorable clinical outcomes. Substantial evidence regarding the pathogenesis and treatment of CAEBV has been accumulated since previous guidelines for the diagnosis of CAEBV were proposed. To reflect this evidence, we updated the guidelines for the diagnosis and treatment of CAEBV to improve clinical management of the disease. The details of the updated guidelines are presented in this report. Diagnosis of CAEBV now requires confirmation of a high copy number of EBV genome and EBV-infected T or NK cells. An EBV DNA load ≥ 10,000 IU/mL in whole blood is proposed as the diagnostic cutoff value for CAEBV in this updated guideline. A standard treatment approach for CAEBV has not been established, and hematopoietic stem cell transplantation (HSCT) is considered the only curative treatment. Chemotherapy can be administered to control disease activity before HSCT.
Keywords: CAEBV; Diagnostic criteria; EBV; Guidelines.
© 2023. The Author(s).
Conflict of interest statement
The authors declare that they have no conflict of interest.
Figures
Similar articles
-
Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.Medicine (Baltimore). 2022 Mar 25;101(12):e29055. doi: 10.1097/MD.0000000000029055. Medicine (Baltimore). 2022. PMID: 35357349 Free PMC article.
-
NK-cell post-transplant lymphoproliferative disease successfully treated by second allogenic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus infection.Int J Hematol. 2022 Apr;115(4):595-599. doi: 10.1007/s12185-021-03271-y. Epub 2022 Jan 10. Int J Hematol. 2022. PMID: 35001347
-
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.Blood. 2011 Jun 2;117(22):5835-49. doi: 10.1182/blood-2010-11-316745. Epub 2011 Mar 31. Blood. 2011. PMID: 21454450 Free PMC article.
-
Chronic active Epstein-Barr virus infection of T-cell type, systemic form in an African migrant: case report and review of the literature on diagnostics standards and therapeutic options.BMC Cancer. 2018 Oct 3;18(1):941. doi: 10.1186/s12885-018-4861-0. BMC Cancer. 2018. PMID: 30285657 Free PMC article. Review.
-
Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development.Front Pediatr. 2019 Feb 5;7:14. doi: 10.3389/fped.2019.00014. eCollection 2019. Front Pediatr. 2019. PMID: 30805320 Free PMC article. Review.
Cited by
-
Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.Front Immunol. 2024 Dec 3;15:1451977. doi: 10.3389/fimmu.2024.1451977. eCollection 2024. Front Immunol. 2024. PMID: 39691713 Free PMC article. Review.
-
Cardiovascular complications in chronic active Epstein-Barr virus disease: a case report and literature review.Front Pediatr. 2025 Jan 10;12:1480297. doi: 10.3389/fped.2024.1480297. eCollection 2024. Front Pediatr. 2025. PMID: 39867694 Free PMC article.
-
Case Report: From IgA nephropathy to pneumonia, periappendiceal abscess, pulmonary arterial hypertension, and basal ganglia calcification: a case of chronic active Epstein-Barr infection in a child.Front Pediatr. 2025 Aug 4;13:1589151. doi: 10.3389/fped.2025.1589151. eCollection 2025. Front Pediatr. 2025. PMID: 40831797 Free PMC article.
-
Chronic active Epstein‒Barr virus colitis, a rare cause of recurrent diarrhea in an immunocompetent female: a case report.BMC Infect Dis. 2025 Jan 9;25(1):50. doi: 10.1186/s12879-024-10422-z. BMC Infect Dis. 2025. PMID: 39789451 Free PMC article.
-
An exploratory study on the differential diagnostic indicators between adult systemic EBV-positive T-cell lymphoproliferative disorders and angioimmunoblastic T-cell lymphoma with multiple EBV infections.Infect Agent Cancer. 2025 Jan 22;20(1):3. doi: 10.1186/s13027-024-00627-x. Infect Agent Cancer. 2025. PMID: 39844250 Free PMC article.
References
-
- Hirai Y, Asada H, Hamada T, Kawada JI, Kimura H, Arai A, et al. Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy. J Dermatol. 2023;50(7):e198–e205. - PubMed
-
- Li W. The 5(th) edition of the World Health Organization classification of hematolymphoid tumors. In: Li W, editor. Leukemia. Brisbane (AU): Exon Publications; 2022. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials